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Background: To evaluate immunity against influenza, mouse challenge studies are typically performed by
intranasal instillation of a virus suspension to anesthetized animals. This results in an unnatural environment in the
lower respiratory tract during infection, and therefore there is some concern that immune mechanisms identified in
this model may not reflect those that protect against infectious virus particles delivered directly to the lower
respiratory tract as an aerosol.
Method: To evaluate differences in protection against instilled and inhaled virus, mice were immunized with
influenza antigens known to induce antibody or cell-mediated responses and then challenged with 100 LD50 A/PR/
8/34 (PR8) in the form of aerosol (inhaled) or liquid suspension (instilled).
Results: Mice immunized with recombinant adenovirus (Ad) expressing hemagglutinin were protected against
weight loss and death in both challenge models, however immunization with Ad expressing nucleoprotein of
influenza A (NPA) or M2 resulted in greater protection against inhaled aerosolized virus than virus instilled in liquid
suspension. Ad-M2, but not Ad-NPA-immunized mice were protected against a lower instillation challenge dose.
Conclusions: These results demonstrate differences in protection that are dependent on challenge method, and
suggest that cell-mediated immunity may be more accurately demonstrated in mouse inhalation studies.
Furthermore, the data suggest immune mechanisms generally characterized as incomplete or weak in mouse
models using liquid intranasal challenge may offer greater immunity against influenza infection than previously
thought.
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Annual influenza epidemics result in approximately 40,000
deaths in the USA and at least one million deaths worldwide
[1,2]. Vaccination provides protection against illness when
the antigens in inactivated split vaccines are antigenically-
matched to the circulating influenza viruses, reflecting the
activity of antibodies that neutralize virus infectivity and
limit virus spread. Both hemagglutinin (HA) and neuramin-
idase (NA)-inhibiting antibodies are independent correlates* Correspondence: Maryna.Eichelberger@fda.hhs.gov
1Division of Viral Products, OVRR, CBER, FDA, 8800 Rockville Pike, Building
29A 1D24, Bethesda, MD 20892, USA
Full list of author information is available at the end of the article
© 2013 Rivers et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orof immunity [3]. However, cell mediated immunity contrib-
utes to virus clearance, with the number of IFN-γ secreting
T cells correlating with the efficacy of live, attenuated influ-
enza vaccine in children [4].
Efforts are currently being made to develop universal in-
fluenza vaccines that offer broad protection by using target
antigens that are conserved across influenza A subtypes:
these antigens include nucleoprotein (NP), Matrix (M), the
conserved stem region of HA, neuraminidase (NA), and
M2. Several publications show that adenovirus (Ad) pro-
vides a suitable vector for delivery of M2 and NP antigens
[5-8]. Adenovirus expressing M2 is known to induce high
M2-specific antibody titers that bind to a highly conserved
region of M2 that is extracellular (M2e) as well as T celltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are sufficient to protect against challenge with PR8 [9].
These antibodies do not act alone, relying on FcR +NK
cells to kill the M2-expressing infected cells [10]. Immune
responses to NP expressed by recombinant adenovirus in-
clude both antibody and CD8+ T cell responses, with the
NP-specific CD8+ T cells and not antibodies contributing
to virus clearance. While the lung parenchyma contains
some NK [11] and memory T cells [12], these cell types are
recruited in substantial numbers from the circulation. Re-
cruitment is a response to chemokines produced by
infected cells or activated macrophages – NK cells migrate
toward a variety of soluble mediators expressed at infected
or inflammatory sites (reviewed in [13]) and there is evi-
dence that IL-15 is responsible for recruitment of
influenza-specific CD8+ T cells to the infected lung [14].
The animal models used in preclinical studies of these
vaccines include mice, guinea pigs and ferrets [15-17].
These animal models typically utilize an intranasal or intra-
tracheal route of virus challenge, with virus delivered in a
liquid suspension to anesthetized animals so that natural
reflexes to swallow or sneeze are avoided. The volume ad-
ministered is substantial, ensuring that virus is deposited in
the lower respiratory tract. This large challenge volume is
likely to impact normal lung physiology, infection kinetics,
as well as the subsequent induction of innate responses and
recall of B and T cell memory. This presents conditions
throughout the respiratory tract that are not representative
of natural infection and we hypothesize, may result in re-
duced capacity of some immune mechanisms to protect
against virus challenge. Influenza can be transmitted by
aerosol and by direct contact with secretions or fomites
[18]. While it is debated which mechanism is predominant,
infectious aerosols are likely a common means of transmit-
ting influenza because very small droplets that are formed
when individuals sneeze or cough, can be inhaled and de-
posited in the lower respiratory tract [19]. A review of re-
cent animal and human studies point to the importance of
aerosolization in influenza transmission [20].
Early mouse studies show that fewer infectious units are
required to infect mice by inhalation than instillation [21]
and that for direct deposition in the lower respiratory tract,
the aerosolized droplets should be <10 μm in diameter [22].
It is reasonable to expect that greater pathology and more
severe disease would be observed when virus is adminis-
tered as an aerosol compared to an instilled liquid suspen-
sion. This is indeed the case [23] with inoculation of a virus
aerosol resulting in replication in Type II pneumocytes, the
cell type observed as targets of natural human influenza in-
fection, supporting the concept that inhalation of virus par-
ticles is likely an important mode of transmission in
humans [24].
The aggravated disease experienced when virus is admin-
istered as an aerosol is clearly evident for A/Vietnam/1203/2004 (H5N1) which is not lethal by instillation in ferrets,
but when administered as an aerosol is neurotropic and
more pathogenic in this species [25]. Differences in the viral
load, infectivity and pathogenesis when animals are chal-
lenged by different methods raise concern that a different
magnitude or quality of the immune response would be re-
quired to control infection initiated by inhaled or instilled
virus. We have established a mouse influenza inhalation
model using nose-only exposure to virus contained within
aerosol particles < 2 μm mass median aerodynamic diam-
eter, and determined the LD50 of mouse-adapted A/PR/8/
34 (PR8) delivered under these conditions [26]. We demon-
strated that approximately 10-20 fold less aerosolized virus
results in death than instilled virus, a difference previously
noted by others [27]. In this study we compare the ability
of different vaccination strategies to protect mice against a
lethal dose of inhaled and instilled influenza virus.
Results and discussion
Immunization with live virus and recombinant adenovirus
(Ad) expressing influenza proteins
BALB/c mice were exposed intranasally to a sublethal
dose of PR8 (H1N1) or a heterologous reassortant H3N2
virus X-31, or vaccinated intramuscularly with recom-
binant adenovirus (Ad) expressing HA, M2, and NP of
influenza A viruses (Ad-NPA), or NP of influenza B vi-
ruses (Ad-NPB). The latter vaccine group as well as
naïve mice served as negative controls since these mice
should not be protected against challenge with PR8.
Three weeks after vaccination, the mice were bled and
hemagglutination inhibition (HAI) antibody titers mea-
sured. Mice immunized with Ad-HA, but not Ad-M2 or
Ad-NP had HAI titers of approximately 1:100 showing
that this vaccination strategy is effective at inducing an
antibody response. The capacity of Ad-M2 and Ad-NP
to induce M2-specific antibodies and NP-specific CD8+
T cells, has been established by others using these same
recombinant adenovirus preparations [5,6,28]. HAI anti-
bodies reactive with PR8 were also present in the sera of
mice exposed to sublethal dose of PR8 (HAI titers of ap-
proximately 1:600), but not following X-31 (H3N2) ex-
posure. As others have reported, NP-specific CD8+ T
cells are activated after live influenza A virus infection,
and are recruited in substantial numbers to the lungs
following challenge with virus that is of a different sub-
type [29].
Virus replication in the lungs of vaccinated mice is similar
4 days after inhaled and instilled PR8 challenge
Five weeks after virus exposure or vaccination, equal
numbers of mice (n = 10) in each vaccine group were ex-
posed to PR8 as an inhaled aerosol or as an instilled liquid
suspension. Aerosol challenge was conducted as described
in Methods and Materials, using a nose-only exposure
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was conducted by placing drops of a virus suspension
onto the nares of anesthetized mice. The same lethal dose
(100 LD50) was used; since BALB/c mice die when 10-fold
lower amount of PR8 is inhaled compared to intranasal in-
stillation [26], the amount of virus used in the inhalation
challenge was approximately 10-fold less than in the instil-
lation challenge.
Five mice in each group were sacrificed 4 days after
challenge and lungs removed for virus titration; the clin-
ical signs of disease and mortality were monitored in the
remaining animals. These results show similar amounts of
virus in the lungs of challenged mice, regardless of the
challenge method (Figure 1). At this time point, virus was
not detected in the lungs of mice previously exposed to
PR8 or vaccinated with rAd-HA. There was a significant
reduction in lung virus titers for mice previously exposed
to the heterologous X-31 virus, providing evidence that
heterosubtypic immunity induced by previous live virus
infection, provides similar protection against inhaled and
instilled virus. However, immunization with Ad-M2 and
Ad-NPA did not reduce day 4 virus titers after either in-
halation or instillation.
Complete immunity against both inhaled and instilled
influenza in mice previously exposed to live homologous
or heterologous virus, or vaccinated with Ad-HA
Mice that had previously been exposed to infectious PR8
or that had been immunized with rAd-HA had no virus
in their lungs 4 days after either inhalation or instillation
of 100 LD50 of the homologous virus (Figure 1). Not
only were these mice protected from infection, they were
fully protected against weight loss (Figure 2) and death
(Figure 3). This protection correlates with the presence























Figure 1 Comparison of virus titers in the lungs of vaccinated mice a
titers (TCID50/ml) are shown for mice challenged by instillation (grey bars) and
per group) collected on day 4 post-challenge, and homogenized in 1 ml of se
line is the limit of quantification for this assay.Although some virus replication was measured in the
lungs, mice previously exposed to heterologous live
X-31 virus were completely protected against weight
loss (Figure 2) and death (Figure 3) after both inhaled
and instilled virus challenge. These mice did not have
antibodies that inhibit either HA or NA activities of
the challenge virus, PR8 (not shown). As reported in
numerous studies of heterologous protection, this pro-
tection is usually mediated by influenza-specific CD4+
and CD8+ T cells that kill infected cells [5,29], al-
though antibodies to conserved antigenic epitopes,
such as M2e, may also contribute to heterosubtypic
immunity [9,30,31].
Immunity against inhaled but not instilled influenza in
mice vaccinated with recombinant Ad-M2 or Ad-NPA
Ad-M2, Ad-NPA, and Ad-NPB-immunized mice lost weight
at the same rate as the naïve mice after challenge with a li-
quid suspension of PR8 (Figure 2). These groups of mice all
died by day 8 post-challenge (Figure 3). Interestingly, this
was one day later than the challenged naïve mice died,
suggesting some benefit of the Ad-M2, Ad-NPA and Ad-
NPB immunizations. In contrast, weight loss after aerosol
challenge of the Ad-M2 and Ad-NPA-immunized mice
slowed 3 days after aerosol challenge, although their
weights remained significantly less than the Ad-HA group
(p < 0.001, two-way repeated measures ANOVA) and nei-
ther group regained all weight by day 10 post-challenge.
The M2-immunized mice were partially protected from this
aerosol challenge, with survival of 4 of 5 mice whereas all
the naïve mice succumbed to infection by day 8 post-
inhalation challenge. Survival between Ad-NPB-immunized
and Ad-M2 or Ad-NPA-immunized mice was not different,
but trended towards significance (p = 0.054). As noted for
challenge with instilled virus, immunization with Ad-NPB
provided a small but consistent benefit, with 1 of the 5Ad-HA Ad-M2 Ad-NPa Ad-NPb
instilled challenge virus
inhaled challenge virus
fter instillation and inhalation PR8 challenge. Geometric mean virus
inhalation (white bars). Virus titers were determined for lungs (5 mice





























































Figure 2 Mice immunized with rAd-M2 and rAd-NP are protected against weight loss when virus is inhaled, but not when virus is
instilled. The average percent of starting weight for each group is shown for mice that were challenged by (A) instillation and (B) inhalation.
Mice in each group (n = 5) were weighed individually on each day after challenge. Each graph shows the percent group mean change in weight
relative to the baseline body weights, with error bars indicating the standard deviation for the group.
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peat experiments with larger numbers of mice per group
are needed to verify the significance of these findings.
Since the mice used in this study were from the same
birth cohort and immunized with the same vaccine prepa-
rations at the same location and time, differences in pro-
tection against instilled and inhaled virus could reflect
differences in virus load and/or differences in the capacity
of the immune response to protect these different chal-
lenge conditions. In mice, lung virus titers are usually not
reflective of input dose and therefore we were not sur-
prised by the similar virus loads measured 4 days after
challenge with inhaled and instilled virus (Figure 1). How-
ever, since the LD50 of inhaled virus was 10-fold less than
the instilled virus, the number of infectious particles (ap-
proximately 870 vs 5160 PFU/mouse [26]) was clearlydifferent and therefore an additional experiment was
conducted to test whether the initial dose explained the
difference in protective capacity. Ad-M2 and Ad-NPA-
immunized mice were therefore challenged by intranasal
instillation with similar total infectious units of PR8 as
had been inhaled. This amount of virus was therefore
equivalent to 10 LD50 in the instillation model.
This experiment included a group challenged by instil-
lation with 100 LD50 PR8, repeating the first experiment.
Weight loss and survival of groups challenged with 100
LD50 PR8 were the same as noted previously. As for this
high challenge dose, the mice immunized with Ad-HA
were fully protected against virus replication, weight
loss and death when challenged with the low virus
dose (Figure 4). The rate at which mice in the Ad-
NPA-immunized group lost weight was similar to that
A. Instillation
Day post-challenge Day post-challenge
Day post-challenge Day post-challenge



































































Figure 3 Mice immunized with rAd-M2 and rAd-NPA survive inhaled, but not instilled, PR8 challenge. Survival of immunized mice is
shown for (A) instilled, and (B) inhaled virus challenge. Mice in all groups (n = 10) were challenged on the same day; to more easily visualize
differences, naïve, PR8 and X-31-exposed mice are shown in graphs on the left hand side, and groups vaccinated with adenovirus recombinants
expressing HA, M2, NPA and NPB are shown graphically on the right hand side. Since 5 mice were sacrificed in each group on day 4, survival of
the remaining 5 was monitored to the end of the study (12 days post challenge). A key indicating the color code for each group is provided on
the figure. Survival against both instilled or inhaled virus challenge was significantly greater for mice previously infected with either PR8 or X31
than naïve mice (Mantel-Cox test, p < 0.001); similarly survival of mice immunized with Ad-HA was greater than Ad-NPB-immunized mice (control
group) when challenged with instilled or inhaled virus challenge (p < 0.001). The difference in survival between Ad-NPB-immunized and Ad-M2 or
Ad-NPA-immunized mice was not statistically different when challenged with instilled virus, but trended towards significance (p = 0.054) for mice
challenged by inhalation.
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served when the Ad-NPA mice were challenged with a
higher dose of instilled PR8, all mice in this group died
by day 8 post-challenge. In contrast, although there
was variability in the weight loss for Ad-M2-immunized
mice, the average percent weight loss was less after
challenge with the low dose compared with the higher
dose (Figure 4B vs Figure 2A), and all mice survived
(Figure 4C vs Figure 3A). This result demonstrates
that M2-mediated immune protection against instilled
virus is dependent on the dose of virus inoculated.
Clearly the effectiveness of M2 and NP-specific im-
munity, but not HA-specific immunity, is compromised
when mice are challenged by instillation. We therefore pre-
dict that instillation impacts the environment in the lower
respiratory tract, influencing the function of some immune
mechanisms. This appears to correlate with the type of
immunity that contributes to protection: HA-specific
antibodies induced by Ad-HA protected against bothinhalation and instillation challenge, while M2-specific
antibodies that rely on NK cells to kill infected cells pro-
vided protection against infection that was dependent on
the challenge dose, and NP-specific CD8+ T cells, the ef-
fector cells induced by Ad-NPA-immunization, provided
some protection against inhaled but not instilled virus
challenge. This suggests that for the immunization regi-
men we have used, antibody-mediated immunity is effect-
ive regardless of challenge method, while cell-mediated
immunity is more effective against virus that is inhaled
than instilled into the lungs.
Challenge by inhalation of very small virus-containing
aerosol particles has a lower LD50 dose [26] and therefore
a simple explanation for the difference in protection was
that a smaller number of virions enter the lower respira-
tory tract of mice inhaling virus than in mice exposed to
instilled virus. We tested this idea by inoculating mice
with 10-fold less instilled virus. Our results showed this



































































Figure 4 (A) Virus titers, (B) weight loss and (C) mortality of
10LD50 instilled PR8. Groups of mice (n = 10) were immunized as
previously and challenged by instillation of PR8. Four days after
challenge, 5 mice in each group were euthanized to allow titration of
virus in the lungs, the weight and survival of the remaining mice was
monitored until day 12. (A) shows geometric mean virus titers, together
with the standard deviation; the dashed line is the limit of quantification
for this assay. (B) shows the percent reduction in weight relative to the
baseline body weights, with error bars showing standard deviation. A
key for the groups is shown to the right of this graph. (C) shows percent
survival of mice in each group. A key for these groups is shown to the
right of the graph. Survival of mice vaccinated with Ad-HA and Ad-M2
was significantly greater (Mantel-Cox test, p = 0.0016) than mice
immunized with Ad-NPA or Ad-NPB. The latter 2 groups were not
different from one another or naïve mice.
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ber of inhaled and instilled virus particles.
Our results are reflective of published reports show-
ing that vaccination strategies eliciting influenza virus-
specific CD8+ T cells do not protect mice against
intranasal challenge with a virus suspension [32], even
though activated CD8+ T cells are capable of protectingmice when transferred directly to the lung [33]. A number
of reasons have been proposed for this discrepancy [32],
one being that compared to transfer of influenza-specific
effector T cells, few influenza-specific CD8+ T cells traffic
to the lung. Our findings of protection against inhaled, but
not instilled PR8 in Ad-NPA-vaccinated mice suggests that
the milieu in the lower respiratory tract is dependent on
the method of challenge, with recruitment and/or effector
function of CD8+ Tcells supported when aerosolized virus,
but not a liquid suspension, is used to challenge the mice.
We propose that this is potentially due to a difference in
the chemokine gradient needed for recruitment of NK and
CD8+ T cells. It is feasible that the liquid instilled into the
lower respiratory tract during challenge prevents establish-
ment of the optimal chemokine gradients by direct dilution
of these soluble mediators, or alternatively, activation of
physiologic responses such as beating of cilia or secretion
of mucins remove chemokines or prevent effective contact
between T cells and the infected epithelium. The hypoth-
esis that instillation disrupts chemokine gradients could be
tested by comparing the concentrations of these soluble
factors in vivo, and measuring the kinetics or magnitude of
NK or T cell recruitment to the infected lung.
While a difference in chemokine gradient provides a po-
tential reason for cell-mediated protection against inhaled
but not instilled virus, there are other explanations to con-
sider. For example, differences in the cell-types infected or
innate mechanisms activated may result in more effective
clearance of inhaled than instilled virus by influenza-
specific CD8+ T cells. Future experiments should therefore
examine the histopathology of lungs from infected mice to
determine the number and types of inflammatory cells
recruited to the lungs, and to compare extent of infection,
cell types infected, and cellular damage as viral or immune
pathology could also contribute to the differences in protec-
tion against instilled and inhaled virus. Other factors that
warrant testing include the potential impact of isoflurane
on instilled virus infectivity and function of responding cells
[34], and possible differences in immune responses induced
in the upper respiratory tract by instilled and inhaled virus.
Further experiments are clearly needed to identify the rea-
sons for the difference in Ad-NPA-induced protection
against instilled and inhaled virus.
Our results show that mice were fully protected
against lethal PR8 challenge by prior exposure to the
heterosubtypic virus, X31. While antibodies contribute
to cross-protection [30], cell-mediated immunity plays
a significant role in immunity with large numbers of
memory NP-specific CD8+ T cells recruited to the
lungs [35]. Our results showing ineffective protection
of Ad-NP-immunized mice against instilled virus in
our model using a single vaccine dose suggest that the
NP-specific immune response, and possible also pro-
tection against instilled virus, could be improved by
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with adjuvant.
In summary, we compared protection against inhaled
and instilled virus in mice previously exposed to hom-
ologous and heterosubtypic virus, or previously immu-
nized with recombinant adenoviruses expressing HA,
M2 or NP. Our results show similar protection against
inhaled and instilled challenge for mice that were previ-
ously infected or vaccinated with Ad-HA, but not for
mice immunized with Ad-M2 or Ad-NPA. In these latter
groups, there was significant protection against inhaled,
but not instilled PR8. These results suggest immune
mechanisms often characterized as weak, such as NK or
CD8+ T cell-mediated killers, may play a more signifi-
cant role in protecting against disease and death than
previously suggested from studies in which mice were
challenged by instillation of a liquid virus suspension.
Our data suggest that animal models using aerosol chal-
lenge may be a suitable approach to evaluate the poten-
tial efficacy of influenza vaccines for which cell-mediated
responses are the correlate of immunity.
Methods and materials
Virus and vaccine preparations
A/PR/8/34 (H1N1) and A/HK/68 × 31 (H3N2, X31) virus
stocks were prepared by inoculating 9-11 day old embryo-
nated chicken eggs. The allantoic fluid was harvested 60-72
hr post-inoculation, cell debris removed by centrifugation
and aliquots stored at -80°C until further use. Infectious titer
of each stock was determined by titration on MDCK cells in
a standard TCID50 assay as previously described [36]. Mice
were rendered immune to the challenge virus (positive
control) by immunization with a sublethal dose of live
virus, with intranasal delivery under isoflurane anesthesia.
Mice were immunized with individual influenza proteins
using recombinant adenoviruses (rAd) that were adminis-
tered intramuscularly (50 μl containing 1010 virus parti-
cles). The Ad5-ΔE1ΔE3 vector was used to express HA
(rAd-HA), M2 (rAd-M2) and NP (rAd-NP). rAd-M2 was
kindly provided by Dr Suzanne Epstein (CBER, FDA), and
rAd expressing nucleoprotein (NP) was kindly provided by
Dr Gary Nabel (VRC, NIH). The rAd-NPA construct in-
duces NP-specific CD8+ T cells in BALB/c mice [5,9]. The
HA gene of PR8 was amplified using primers Hind III-H1
and Bam HI-H1, and the Hind III/Bam HI product
inserted into pVQpacAd5CMVK-NpA (ViraQuest, North
Liberty, IA). The construct was used to generate rAd ex-
pressing HA, by transfecting the construct into human
embryonic kidney 293 cells that stably express E1A and
E1B genes. Bulk rAd stocks were produced by ViraQuest,
Inc. The recombinant adenovirus vectors expressing influ-
enza A NP and consensus M2 that we used in our study
have been described previously [8,9]. All virus stocks were
stored in aliquots at -80°C.Mice and study design
Female BALB/c mice were purchased from The Jackson
Laboratories (Bar Harbor, ME) and housed at Center for
Biologics Evaluation and Research (CBER) where they
were immunized. Mice that were subjected to nose-only
inhalation challenge were shipped to Southern Research
Institute (SR, Birmingham, AL) approximately 1 week be-
fore the start of the study. Cage size and animal care
conformed to the guidelines prescribed in the Guide for
the Care and Use of Laboratory Animals, the U.S. Depart-
ment of Agriculture through the Animal Welfare Act.
Mice were challenged by instillation at CBER, and nose-
only inhalation at SR. All experiments were performed
under protocols 2006-22 and 10-217 approved by the Insti-
tutional Animal Care and Use Committees at CBER and
SR, respectively. The mice were approximately 15 weeks of
age and weighed between 19 and 26 grams at the time of
virus challenge by inhalation or instillation.
Inhalation challenge system
The murine inhalation challenge system consisted of
six components: a compressed air source, a bioaerosol
delivery line, a 24-port radial nose-only inhalation
challenge plenum, a bioaerosol characterization plat-
form, an air handling station, and an exhaust platform.
The bioaerosol delivery line consisted of a Collison
3-Jet Nebulizer (BGI Inc., Waltham, MA), a radial in-
line aerosol mixer (In-Tox Products, LLC; Albuquerque,
NM), and a filtered air passive dilutor. The radial nose-
only inhalation challenge plenum (In-Tox Products) was
fitted with Positive Flow-By™ restraint tubes (In-Tox
Products) and isoaxial sample collection ports that
interfaced with the bioaerosol characterization platform.
The bioaerosol characterization platform included air sam-
pling impingers, Model 7541 (Ace Glass, Inc., Vineland,
NJ), and an Aerosol Particle Sizer™ Spectrometer (APS,
TSI Inc., Shoreview, MN). The air handling station
interfaced with the bioaerosol delivery line, the
bioaerosol characterization platform, and the exhaust
platform and consisted of computer regulated gas flow
and pressure controllers (Alicat Scientific, Inc., Tucson,
AZ). The exhaust platform consisted of HEPA filters, a
differential pressure magnehelic, and a vacuum pump.
The bioaerosol delivery line, inhalation challenge ple-
num, and bioaerosol characterization platform were
placed inside a SterilGARD® III Advance™ (Baker Com-
pany; Sanford, ME) biological safety cabinet (BSC). The
inhalation challenge plenum was maintained at a slightly
negative pressure relative to the BSC. The BSC was
maintained at a slightly negative pressure with respect to
the Animal Biosafety Level-2 laboratory. Temperature and
relative humidity within the inhalation challenge plenum
were monitored using a Humidity Temperature Meter
(Omega Engineering, Stamford, CT). Inhalation challenge
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ing all challenges with a Model 5800 Intelligent Oxygen
Monitor (Hudson RCI, Durham, NC).
Prior to conducting inhalation challenges, the system
was characterized using PR8 virus [26]. Characterization
included achieving and maintaining a target range of aero-
sol concentrations as determined by plaque assay analysis
of impinger samples, and the demonstration of the aerosol
particle size distribution of the challenge aerosol deter-
mined by APS analysis.
Virus challenge
Inhalation of virus: On three consecutive days prior to in-
halation challenge, mice were trained in the nose-only
inhalation restraint tubes. On the day of challenge, a
Collison 3-Jet Nebulizer was filled with virus stock suspen-
sion and connected to the bioaerosol delivery line. The di-
lution of virus needed to deliver 100 LD50 had previously
been determined [26]. A pre-spray nebulizer suspension
sample was collected to confirm that the correct virus dilu-
tion had been prepared. Mice were placed in nose-only re-
straint tubes and connected to the inhalation challenge
plenum using Positive Flow-By™ nose cones (In-Tox Prod-
ucts, LLC; Albuquerque, NM). Groups of mice were ex-
posed to nebulized virus for 30 minutes. The start of the
challenge period (T = 0) began once the nebulizer was acti-
vated and set at 30 psi. Inhaled dose (approximately 870
PFU) was calculated as the product of aerosol concentra-
tion, murine minute ventilation (0.062 L/min [37]), and
challenge duration.
Instillation of virus: Groups of mice were anesthetized
by exposure to 3% isoflurane in the presence of 3% O2
and then inoculated with 30 μl of PR8 diluted in PBS
(approximately 5,160 PFU), by applying droplets of the
suspension to both nares.
All mice were observed twice daily during quarantine and
study periods for signs of morbidity and mortality. Body
weights were recorded daily. Animals that had lost ≥25% of
their starting weight were euthanized. These mice were
moribund, with hunched posture, inactivity and no re-
sponse to handling. Survival curves were plotted taking into
account both euthanized and animals found dead.
Statistical analyses
Statistical analyses for body weight data were performed
using the Provantis automated data collection system
(Instem; Staffordshire, UK). Differences in weight between
groups were determined by two-way repeated measures
ANOVA (Microsoft Excel 2003, Redmond, WA) and differ-
ences in survival were determined by log-rank Mantel-Cox
test using GraphPad PRISM 5 software. The mean, stand-
ard deviation, and coefficient of variance were calculated
for aerobiology data using Excel or SigmaPlot (Systat Soft-
ware, Inc., San Jose, CA) when appropriate.Virus titration
The 50% tissue culture infectious dose (TCID50) was de-
termined by titration on MDCK cells (ATCC line CCL-34)
following a standard procedure that was previously de-
scribed [36]. Briefly, serial ten-fold dilutions of each lung
homogenate were inoculated into quadruplicate wells of a
96-well plate containing a monolayer of MDCK cells.
After 1 h in a CO2 incubator at 37°C, an equal volume of
serum-free medium containing 3% BSA and TPCK-
treated trypsin (5 μg/ml) was added. After 3 days incuba-
tion, the remaining cells were stained with crystal violet in
gluteraldehyde. The TCID50 titer was defined as the in-
verse of the dilution that showed cytopathic effect in 50%
of the wells.
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